文献速递肝肾功能剂量调整特殊人群用药

不同程度肾或肝损伤对每周一次胰岛素icodec药代动力学的影响

The Effect of Various Degrees of Renal or Hepatic Impairment on the Pharmacokinetic Properties of Once-Weekly Insulin Icodec.
PubMed 文献 · Clin Pharmacokinet · 2024-05-09

本研究通过两项开放标签、平行组、单次给药(1.5 U/kg皮下注射)试验,分别评估肾功能不全(58例)和肝功能不全(25例)对icodec药代动力学的影响。结果显示,轻至重度肾损伤及终末期肾病患者icodec总暴露量略高,轻至中度肝损伤也略高,但药代动力学曲线形态未改变,血清白蛋白水平无显著影响。结论认为无需针对肾或肝损伤调整icodec剂量。

要点

  • 肾损伤(轻至重度及终末期肾病)使icodec总暴露量轻度升高,但药代动力学曲线形态不变。
  • 轻至中度肝损伤使icodec暴露量轻度升高,重度肝损伤与正常肝功能无统计学显著差异。
  • icodec按个体需求给药,肾或肝损伤患者无需特定剂量调整。

核心结论

  • 肾或肝损伤对icodec暴露量的轻度升高临床相关性有限,因icodec应按个体需求给药。
  • 肾或肝损伤患者无需调整icodec剂量。

研究设计与样本

  • 两项开放标签、平行组、单次给药(1.5 U/kg皮下注射)试验。
  • 肾损伤试验纳入58例,分配至正常肾功能、轻度、中度、重度肾损伤或终末期肾病组。
  • 肝损伤试验纳入25例,分配至正常肝功能、轻度(Child-Pugh A)、中度(B)或重度(C)肝损伤组。
  • 给药后频繁采血进行药代动力学分析直至第35天。

主要发现

  • icodec药代动力学曲线形态不受肾或肝损伤影响。
  • 与正常肾功能相比,轻度肾损伤的总暴露量估计比值(95%CI)为1.12(1.01; 1.24),中度为1.24(1.12; 1.37),重度为1.28(1.16; 1.42),终末期肾病为1.14(1.03; 1.28)。
  • 与正常肝功能相比,轻度肝损伤的总暴露量估计比值(95%CI)为1.13(1.00; 1.28),中度为1.15(1.02; 1.29)。
  • 重度肝损伤与正常肝功能之间无统计学显著差异。
  • 血清白蛋白水平(范围2.7-5.1 g/dL)对icodec暴露量无统计学显著影响。

临床怎么用

  • 临床使用icodec时,无需根据肾功能或肝功能损伤程度进行剂量调整。
  • 应依据患者个体需求确定icodec剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Icodec is a once-weekly insulin being developed to provide basal insulin coverage in diabetes mellitus. This study evaluated the effects of renal or hepatic impairment on icodec pharmacokinetics. METHODS: Two open-label, parallel-group, single-dose (1.5 U/kg subcutaneously) trials were conducted. In a renal impairment trial, 58 individuals were allocated to normal renal function (measured glomerular filtration rate ≥ 90 mL/min), mild (60 to < 90 mL/min), moderate (30 to < 60 mL/min) or severe (< 30 mL/min) renal impairment or end-stage renal disease. In a hepatic impairment trial, 25 individuals were allocated to normal hepatic function or mild (Child-Pugh Classification grade A), moderate (grade B) or severe (grade C) hepatic impairment. Blood was sampled frequently for a pharmacokinetic analysis until 35 days post-dose. RESULTS: The shape of the icodec pharmacokinetic profile was not affected by renal or hepatic impairment. Total icodec exposure was greater for mild (estimated ratio [95% confidence interval]: 1.12 [1.01; 1.24]), moderate (1.24 [1.12; 1.37]) and severe (1.28 [1.16; 1.42]) renal impairment, and for end-stage renal disease (1.14 [1.03; 1.28]), compared with normal renal function. It was also greater for mild (1.13 [1.00; 1.28]) and moderate (1.15 [1.02; 1.29]) hepatic impairment versus normal hepatic function. There was no statistically significant difference between severe hepatic impairment and normal hepatic function. Serum albumin levels (range 2.7-5.1 g/dL) did not statistically significantly influence icodec exposure. CONCLUSIONS: The clinical relevance of the slightly higher icodec exposure with renal or hepatic impairment is limited as icodec should be dosed according to individual need. No specific icodec dose adjustment is required in renal or hepatic impairment. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT03723785 and NCT04597697.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Haahr H, Cieslarová B, Hingst JR, et al. The Effect of Various Degrees of Renal or Hepatic Impairment on the Pharmacokinetic Properties of Once-Weekly Insulin Icodec. Clin Pharmacokinet. 2024. PMID: 38722461. doi:10.1007/s40262-024-01375-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。